MRNA

mRNA-1273

COVID-19 Vaccine

Phase 2/3

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

TITLE: mRNA-1273 COVID-19 Drug

  • ClinicalTrial.gov (NCT04283461): Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)


WHAT IS THE NEXT CATALYST EVENT?

  • July 2020 Phase 3 trial begins

  • TBD: Additional Phase 2 data 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?  


PRIOR DATA


PRESS RELEASES/EVENTS

MECHANISM OF ACTION / RATIONALE

  • mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the NIH.

Updated by HC

MRNA, mRNA-1273, COVID-19

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

MRNA - Interim analysis of mRN...

Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273). Bull (Optimist) Summary: Highly encouragin...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon